メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ

Comparison of three plasma p-tau217 assays to detect PET-confirmed Alzheimer's pathologies

  • Sayo Matsuura
  • , Kenji Tagai
  • , Harutsugu Tatebe
  • , Ryoji Goto
  • , Hideki Matsumoto
  • , Asaka Oyama
  • , Yuki Momota
  • , Masanori Ichihashi
  • , Yuko Kataoka
  • , Kiwamu Matsuoka
  • , Naomi Kokubo
  • , Tetsuji Kamada
  • , Kenta Osawa
  • , Yoshikazu Chishiki
  • , Sho Moriguchi
  • , Yuki Komatsu
  • , Chie Seki
  • , Keisuke Takahata
  • , Hironobu Endo
  • , Takashi Kudo
  • Makoto Higuchi, Takahiko Tokuda

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

1   !!Link opens in a new tab 被引用数 (Scopus)

抄録

INTRODUCTION: Plasma phosphorylated tau 217 (p-tau217) has emerged as a promising blood-based biomarker for Alzheimer's disease (AD) diagnosis, but cross-platform comparability remains unclear. We evaluated three platforms—single-molecule array (Simoa), Ella, and Lumipulse. METHODS: We measured plasma p-tau217 from 113 participants underwent amyloid and tau positron emission tomography (PET; 55 AD, 36 controls, 22 non-AD; classified by amyloid PET status). Diagnostic performance and PET correlations were assessed across all three platforms. RESULTS: All assays distinguished amyloid-positive from -negative individuals with high accuracy (89%–95%). Simoa showed superior sensitivity, Ella the smallest gray zone in a two-cutoff framework, and Lumipulse strongest tau correlation (r = 0.770). Multiple regression revealed higher amyloid β-values for Simoa/Ella (0.420–0.518) and higher tau β-values for Lumipulse (0.630). All platforms detected elevated p-tau217 in amyloid-positive individuals with substantial tau pathology despite relatively low Centiloid. DISCUSSION: All platforms accurately detect AD with platform-specific differences, which inform platform selection for clinical and research applications. TRIAL REGISTRATION: Clinical Trial Registration: UMIN Clinical Trials Registry (UMIN-CTR), Trial ID: UMIN000057548, Registration Date: April 8, 2025.

本文言語英語
論文番号e70294
ジャーナルAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
巻18
号1
DOI
出版ステータス出版済み - 01-01-2026
外部発表はい

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

  1. SDG 3 - すべての人に健康と福祉を
    SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

  • 臨床神経学
  • 精神医学および精神衛生

フィンガープリント

「Comparison of three plasma p-tau217 assays to detect PET-confirmed Alzheimer's pathologies」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル